EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.

NCT05570149 · clinicaltrials.gov ↗

RECRUITING

Status

500

Enrollment

OTHER

Sponsor class

Conditions

Migraine Disorders

Interventions

DRUG: Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution

Sponsor

IRCCS San Raffaele Roma